CTOs on the Move

Abner Labs

www.abner-labs.com

 
Abner Innovation Laboratories Limited (“Abner Labs”) is a British Columbia, Canada, company formed to acquire Abner Technology Group Limited (“Abner Group”), owner of the ibetmobile sports viewing and betting technology platform. This proprietary, artificial intelligence (“AI”) driven smart technology makes watching and wagering on live sports on any online device as easy as playing video games.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.abner-labs.com
  • Brookfield Place – 181 Bay Street Suite 4400
    Toronto, ON CAN M5J 2T3
  • Phone: 604.561.0840

Executives

Name Title Contact Details

Similar Companies

Acadia Pharmaceuticals

Acadia Pharmaceuticals is a biopharmaceutical company that develops and commercializes therapies for central nervous system disorders. Their focus is on developing treatments for dementia-related psychosis, negative symptoms of schizophrenia, and Rett ...

Armstrong Pharmaceuticals Inc

Armstrong Pharmaceuticals, Inc. was founded in 1955 as a manufacturer of specialty aerosol products. Armstrong produced a wide array of topical, personal care, and pharmaceutical products. Since 1993, Armstrong has focused exclusively on pharmaceutical

Sisters of Saint Joseph of Philadelphia

We are a community of approximately 825 women religious. Originally founded in 1650 in LePuy, France, the Sisters of Saint Joseph came to Philadelphia in 1847. Through our many ministries, including educations, healthcare, social services and parish m...

Veristat

Veristat, a global clinical research organization (CRO), enables sponsors to solve the unique and complex challenges associated with accelerating therapies through clinical development to regulatory approval. With more than 26 years of experience in clinical trial planning and execution, Veristat is equipped to support any development program. Our team has prepared over 100 marketing applications for approval with global regulatory authorities in the last 10 years.

Pharvaris

Pharvaris is a clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of HAE and other bradykinin-mediated diseases. The company brings together executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE. The company reunites the core team responsible for the discovery and approval of the HAE treatment icatibant. With novel small molecules, we have identified and are advancing potent, orally available compounds targeting this clinically proven therapeutic target.